Table 3. Comparison between baseline and end of study markers of hepatic and whole-body insulin sensitivity in non-diabetic participants grouped by change in erythrocyte DHA enrichment (≥2% or <2%).

Variables	DHA ≥2% (n=9)		DHA <2% (n=7)	
	Baseline	End	Baseline	End
Basal endogenous glucose production (Ra) (μmol/min/kg FFM)	15.2 ± 0.8	14.4 ± 0.7	13.4 ± 0.7	14.0 ± 1.0
Low-dose insulin EGP (μmol/min/kg FFM)	8.7 ± 0.9	7.8 ± 0.7	7.1 ± 0.5	6.7 ± 1.0
High-dose insulin total body glucose disposal (Rd) (μmol/min/kg FFM)	35.0 ± 3.1	34.3 ± 4.2	30.4 ± 3.5	35.9 ± 5.5
High-dose insulin total body glucose clearance (MCR) (ml/min/kg FFM)	7.17 ± 0.84	6.79 ± 0.75	6.12 ± 0.73	7.26 ± 1.16
M-value (mg/min/kg)	3.22 ± 0.33	3.21 ± 0.34	3.23 ± 0.61	3.77 ± 0.73
Hepatic insulin sensitivity index (μmol/min/kg FFM) $(mU/L)^{-1}$ x 10^2	0.54 (0.36, 0.82)	0.63 (0.42, 0.89)[**]	0.52 (0.30, 0.67)	0.55 (0.46, 1.42)
Adipose-IR x 10^{-2}	75.5 ± 11.0	109.0 ± 38.9	110.0±27.6	67.9 ± 10.1

Data presented as mean ± SEM or median (25th, 75th percentiles)

Abbreviations: Ra, Rate of appearance of glucose; Rd, rate of glucose disposal; MCR, metabolic clearance rate; FFM, fat free mass; EGP, endogenous glucose production; M-value, glucose infusion rate; IR, insulin resistance

[**]$P<0.01$ between baseline and end of study measurements within the respective groups